# Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

> **NCT03113266** · PHASE2 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 370 (estimated)

## Conditions studied

- Bladder Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** humanized anti-PD-1 monoclonal antibody toripalimab

## Key facts

- **NCT ID:** NCT03113266
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-06
- **Primary completion:** 2020-03-15
- **Final completion:** 2022-02
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03113266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03113266, "Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03113266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*